Is Neuropathy Curable?

Sometimes. Which sometimes you are in depends almost entirely on what caused it — and the cause, unlike the prognosis, is often knowable. When the trigger is vitamin B12 deficiency, complete recovery is common. When it is chemotherapy, about three people in ten still have symptoms six months later. Same word on the discharge letter, two different diseases.

Is neuropathy curable? The cause decides

In a review of 153 episodes of vitamin B12 (cobalamin) deficiency affecting the nervous system, in 143 patients, follow-up was adequate to judge the response to B12 treatment in 121. Every one responded. In 57 of them (47.1%) recovery was complete, with no remaining symptoms or findings on examination, and only 7 episodes left residual long-term moderate or severe disability. Recovery was inversely related to how long symptoms had lasted before treatment started.¹

Chemotherapy reads differently. Across 31 studies and 4,179 patients, prevalence was 68.1% (95% CI 57.7–78.4) in the first month after treatment, 60.0% (36.4–81.6) at three months and 30.0% (6.4–53.5) at six months or more.² Note the width of that last interval. It is honest, and it is why nobody can give you a date.

Asking whether neuropathy is curable without knowing its cause is like asking whether a car is repairable — flat battery or cracked engine block.

The cause is established by testing, not by guessing. In a real share of cases the workup still comes back empty — that is idiopathic neuropathy, and it means the search was thorough rather than careless. Where cancer treatment is the trigger, the neurotoxic classes are taxanes, platinum compounds and vinca alkaloids: over half of patients on those regimens develop neuropathy.⁴ If you want the symptom picture and the mechanism of the chemotherapy form specifically, that is covered in neuropathy after chemotherapy.

Is neuropathy permanent? Why some nerves come back and some don't

A nerve fibre is a wire with insulation. The wire is the axon; the insulation is myelin. Strip the myelin and the cell survives — the body only has to re-insulate, and that generally goes well. Sever the axon and the fibre has to regrow along a path that can approach a metre before it reaches the toes.

In humans that long regrowth usually fails, and slow axonal outgrowth is only half the reason. While the fibre is on its way, the far end of the nerve deteriorates: Schwann cells atrophy and the Schwann cell basal lamina tube — the sleeve that guides a regrowing fibre — is lost, leaving an extracellular environment that actively inhibits regeneration.⁵ The road is still there. The address is gone.

Neuropathy in the feet: why the toes go first

The longest fibres fail first, and they end in the toes — which is why numbness, tingling and burning start at the bottom and climb, and why the hands follow later. Symptoms that are climbing, or that have reached your hands, are new information rather than more of the same. That belongs with your oncologist this week, not at the next scheduled appointment.

Neuropathy medications: what the trials actually show

Drugs for neuropathy exist and they work, with one limit worth stating plainly: they treat the pain, not the nerve. That is no argument against taking them — lying awake with burning feet is its own kind of damage. The American Society of Clinical Oncology (ASCO) is blunt about the ceiling. For established painful chemotherapy-induced neuropathy, duloxetine is the only agent with adequate evidence to support its use, and the amount of benefit is limited. For prevention, no agent is recommended at all.⁶

Read those percentages correctly: they are the share of people who crossed a threshold, not the size of anyone's pain reduction. Cochrane states it in plain numbers — around 3 or 4 out of 10 participants get at least half their pain relieved with gabapentin, compared with 1 or 2 out of 10 on placebo. Against that, 63% report at least one side effect versus 49% on placebo, most often dizziness (19%), drowsiness (14%) and gait disturbance (14%), which matters more than usual when your feet are already numb, and 11% stop the drug because of side effects versus 8.2%.⁹ Both duloxetine and gabapentin are prescription drugs, titrated upward rather than started at the trial dose. And duloxetine being an antidepressant is not a comment on your pain: it is licensed for diabetic neuropathic pain in its own right, and its analgesic effect runs through the descending pathways that damp pain signalling in the spinal cord, so it does not depend on lifting your mood.

What failed in the trials — and one thing that didn't quite

• Acetyl-L-carnitine, sold specifically for neuropathy, made it worse. In 409 women on adjuvant taxane chemotherapy, 1000 mg three times daily for 24 weeks left FACT-Taxane neurotoxicity scores 1.39 points lower over two years (95% CI −2.48 to −0.30, P = 0.01) — and on that scale a lower score means more neuropathy. The difference was most evident at weeks 24, 36 and 52 (−1.68, −1.37 and −1.83).¹¹ ASCO's wording is that its use for prevention "should be discouraged".⁶
• Alpha-lipoic acid, for platinum chemotherapy. The molecule that helps diabetic neuropathy did nothing here: 600 mg three times daily for 24 weeks alongside cisplatin or oxaliplatin, no difference from placebo on any measure. The authors concluded it was ineffective at preventing platinum neurotoxicity — and that with only 70 of 243 patients (29%) completing, the trial also demonstrated a lack of feasibility.¹²
• Goshajinkigan (TJ-107), a traditional Japanese Kampo herbal formula used for this exact indication. In a phase 2 placebo-controlled trial of 89 patients, grade 2 or worse oxaliplatin neurotoxicity occurred in 39% on the drug and 51% on placebo — relative risk 0.76, 95% CI 0.47–1.21.¹³ The confidence interval includes 1, meaning the result is still compatible with no effect at all; the authors called it a promising effect in delaying onset. Unsettled rather than refuted.
• Frozen gloves versus compression gloves. 43 patients enrolled and 38 evaluated, each wearing a frozen glove on one hand and two surgical gloves on the other. Neuropathy came out the same on both sides.¹⁴ That makes the two equivalent to each other. There was no untreated hand, so the trial cannot tell you whether either one works.

The lesson is sharper than "supplements do nothing". A substance that helps neuropathy from one cause can be useless, or harmful, when the cause is different. Anyone offering a supplement for neuropathy without first asking what caused it is selling, not advising.

When the cause is diabetes

Diabetic peripheral neuropathy eventually affects nearly 50% of adults with diabetes, with prevalence estimated between 6% and 51% depending on age, duration of diabetes, glucose control and diabetes type.¹⁵ It is also the cause most often explained in half-truths. The half-truth is "control your sugar and neuropathy won't develop". In type 1, enhanced glucose control cut the risk of clinical neuropathy clearly — an annualised risk difference of −1.84% (95% CI −2.56 to −1.11). In type 2, which accounts for the great majority of patients, the difference was −0.58% (95% CI −1.17 to 0.01) and missed significance at P = 0.06.³

Two findings usually dropped from that summary matter as much. Most secondary outcomes — nerve conduction and vibration threshold — did significantly favour intensive control in both types. And enhanced control significantly increases severe hypoglycaemic episodes, which has to be weighed against the benefit.³ So glucose control measurably protects nerve function whatever it does to the incidence of clinical neuropathy in type 2. If you have done everything right and your feet still burn, you did not break anything.

What you can do without a prescription

• Find the cause, if no one has yet. Blood tests for B12 and HbA1c answer two questions that reshape the whole plan, and this is the only item here that can deliver real recovery.¹
• Report symptoms the day they appear. Once neuropathy becomes intolerable or starts costing you function, ASCO tells oncologists to weigh dose delay, dose reduction, substitution or stopping — against the cancer control that the treatment is buying.⁶ That judgement is theirs, and they can only make it while the course is still running. The time you cannot get back is not the months ahead; it is the weeks spent saying nothing.
• Move, especially when you don't want to. In 355 patients, a six-week individualised home programme of moderate-intensity walking and resistance exercise reduced hot and cold sensations in the hands and feet by 0.46 points on a 0–10 self-reported scale (P = 0.045); numbness and tingling fell 0.42 points, just short of significance (P = 0.061). No equipment. This was a secondary analysis of a phase III trial built to study fatigue, so treat it as encouraging rather than settled.⁴
• Cut the alcohol. It is an independent cause of nerve damage, and it drives the B-vitamin shortfall that makes everything else worse — the interaction with treatment is covered in alcohol and chemotherapy.
• Eat enough. Protein and B-vitamin shortfalls are common during treatment; there is more on this in diet during cancer treatment.

One more thing deserves naming, because it is sold hard. Hericium erinaceus mycelium extract promoted the maturation of oligodendrocyte precursor cells and raised myelin basic protein in cell cultures and cerebellar slices, and oral dosing raised it in the corpus callosum of neonatal rats.¹⁶ An aqueous extract, given orally, promoted peripheral nerve regeneration after peroneal nerve crush injury in rats.¹⁷ But oligodendrocytes are central nervous system cells, and the myelin failing in your feet is made by Schwann cells — a different cell in a different system. Cells and rodents, and no human neuropathy trial. A hypothesis worth watching, not a treatment.

Why people take Lentinan alongside chemotherapy

Lentinan comes from the medicinal mushroom Lentinula edodes. Japan approved it as an addition to stomach-cancer treatment back in 1985,¹⁸ and it has been taken alongside chemotherapy for other cancers ever since¹⁹ — which is why you keep seeing it.

Even though Lentinan has really unexpected plays of arming the immune system to locate and attack cancer cells,²⁰ what additionally matters for you is what happened when someone finally tested it on the exact problem this page is about — neuropathy from chemotherapy.

In 2025, a randomised, double-blind, placebo-controlled trial gave patients an oral Lentinula edodes extract for numbness that had stayed after their oxaliplatin finished. Not a hospital drip — a tablet they swallowed at home. At 1,800 mg a day, numbness fell by more than twice as much as on placebo, and the size of the change was the kind patients actually feel, not just a number on a chart.²¹

Two things worth knowing before you buy anything. Not all extracts are equal — what we recommend, you will find below.

Astaxanthin sits next to it for a different reason. Chemotherapy damages nerves partly through oxidative stress, and in patients on cisplatin, 8 mg a day measurably lowered the marker of that damage.²² Astaxanthin being the strongest antioxidant we know of against singlet oxygen, the form of oxygen damage chemotherapy drives (yes, more than 6,000 times stronger than Vit C!),²³ works wonders for a damaged cell membrane, from inside and outside.²⁴²⁵ It is the supplement for any organ on stress, including eyes²⁶ and skin.²⁷²⁸

If you take one thing from this section: the dose, quality and specific needed extracts are what separate desired outcome from placebo. See below the recommended brand.

Frequently Asked Questions